I have a very newb question - since the IPO will be $12.90, isn't it going to be more difficult to multiply (bag wise) since the price is so high? I was bored last night so went through the list of companies that listed on Nasdaq via ADR and most of the pharma companies I saw are quite low price wise and market cap too.
Obviously we have some amazing potential drugs where as many of those companies are useless but the thought just came to mind that what realistic price can we see of IXHL on Nasdaq since we're starting close to $13?
Add to My Watchlist
What is My Watchlist?